Children’s FLONASE® Allergy Relief Clinical Profile

Children’s FLONASE® Allergy Relief Clinical Profile

Children’s FLONASE® Allergy Relief offers all the benefits of FLONASE® Allergy Relief for children ages 4+, including 24-hour relief of1-14:

  • Nasal congestion
  • Runny nose
  • Sneezing
  • Itchy nose
  • Itchy eyes
  • Watery eyes

How does Children’s FLONASE® Allergy Relief compare?

Children’s FLONASE® Allergy Relief delivers the same trusted, prescription-strength relief as the #1 prescribed INS allergy ingredient*

Children may not be getting the allergy relief they need, which can impact their quality of life

Nondrowsy and minimally systemic, Children’s FLONASE® Allergy Relief is indicated to treat nasal and ocular symptoms of SAR and PAR in children as young as 4 years, and is available OTC in 60-metered spray bottles.1

Does more to block the allergic cascade

Works to block 6 key inflammatory mediators—not just histamine.†20-23

Mechanism vs most allergy pills. FLONASE® Allergy Relief acts on multiple inflammatory mediators (histamine, prostaglandins, cytokines, tryptases, chemokines, and leukotrienes). The exact number and precise mechanism are unknown.

Relieves itchy, watery eyes11-14

Clinicians reported significant reductions in Total Ocular Symptom Scores (TOSS). Symptoms were reduced by 40% at day 7 and 50% at day 14 (mean change from baseline).13

A well-established safety profile trusted by doctors and pharmacists for over 20 years24-27

Children’s FLONASE® is a corticosteroid with low (<1%) systemic absorption26-29

  • Minimizes potential for systemic side effects that are a concern with oral corticosteroids such as prednisone28-29

Children’s FLONASE® Allergy Relief is NOT associated with:

  • Higher blood pressure and is not contraindicated in patients with hypertension, heart disease, diabetes, liver disease, or kidney disease26,27
  • Anticholinergic side effects commonly associated with some other allergy medications, such as drowsiness, dry mouth, nervousness, dizziness, or sleeplessness26,27

RESOURCES

Patient education materials and more

PATIENT TYPES

Explore different patient types and find out which product is right for your patients

DOSING

Learn more about Children’s FLONASE® Allergy Relief Administration and Dosing

References

1. FLONASE® Drug Facts Label. 2. Greiner, A. N., Hellings, P. W., Rotiroti, G., and Scadding, G. K. Allergic Rhinitis. The Lancet. 378(9809): 2112-2122, 2011. 3. Wallace, D. V., Dykewicz, M. S., Bernstein, D. I., Blessing-Moore, J. et al. The Diagnosis and Management of Rhinitis: An Updated Practice Parameter. Journal of Allergy and Clinical Immunology. 122(2 SUPPL.): S1-S84, 2008. 4. Nathan, R. A., Bronsky, E. A., Fireman, P., Grossman, J. et al. Once Daily Fluticasone Propionate Aqueous Nasal Spray Is an Effective Treatment for Seasonal Allergic Rhinitis. Annals of Allergy. 67(3): 332-338, 1991. 5. Banov, C. H., Woehler, T. R., LaForce, C. F., Pearlman, D. S. et al. Once Daily Intranasal Fluticasone Propionate Is Effective for Perennial Allergic Rhinitis. Annals of Allergy. 73(3): 240-246, 1994. 6. Dykewicz, M. S., Kaiser, H. B., Nathan, R. A., Goode-Sellers, S. et al. Fluticasone Propionate Aqueous Nasal Spray Improves Nasal Symptoms of Seasonal Allergic Rhinitis When Used As Needed (Prn). Annals of Allergy, Asthma and Immunology. 91(1): 44-48, 2003. 7. Scadding, G. K., Lund, V. J., Jacques, L. A., and Richards, D. H. A Placebo-Controlled Study of Fluticasone Propionate Aqueous Nasal Spray and Beclomethasone Dipropionate in Perennial Rhinitis: Efficacy in Allergic and Non-Allergic Perennial Rhinitis. Clinical and Experimental Allergy. 25(8): 737-743, 1995. 8. Van As, A., Bronsky, E. A., Dockhorn, R. J., Grossman, J. et al. Once Daily Fluticasone Propionate Is As Effective for Perennial Allergic Rhinitis As Twice Daily Beclomethasone Diproprionate. Journal of Allergy and Clinical Immunology. 91(6): 1146-1154, 1993 9. Data on file, GlaxoSmithKline. (GSK: Result Summary for Study FNM40184. Http://Www.Gsk-Clinicalstudyregister.Com/. 12-19-2005) 10. Ratner, P. H., Howland III, W. C., Jacobs, R. L., Reed, K. D. et al. Relief of Sinus Pain and Pressure With Fluticasone Propionate Aqueous Nasal Spray: A Placebo-Controlled Trial in Patients With Allergic Rhinitis. Allergy and Asthma Proceedings. 23(4): 259-263, 2002. 11. Haye, R. and Gomez, E. G. A Multicentre Study to Assess Long-Term Use of Fluticasone Propionate Aqueous Nasal Spray in Comparison With Beclomethasone Dipropionate Aqueous Nasal Spray in the Treatment of Perennial Rhinitis. Rhinology. 31(4): 169-174, 1993. 12. Bernstein, D. I., Levy, A. L., Hampel, F. C., Baidoo, C. A. et al. Treatment With Intranasal Fluticasone Propionate Significantly Improves Ocular Symptoms in Patients With Seasonal Allergic Rhinitis. Clinical and Experimental Allergy. 34(6): 952-957, 2004. 13. DeWester, J., Philpot, E. E., Westlund, R. E., Cook, C. K. et al. The Efficacy of Intranasal Fluticasone Propionate in the Relief of Ocular Symptoms Associated With Seasonal Allergic Rhinitis. Allergy and Asthma Proceedings. 24(5): 331-337, 2003. 14. Data on file, GlaxoSmithKline. (GSK: Result Summary for Study FNM30034. Http://Www.Gsk-Clinicalstudyregister.Com/. 5-12-2005) 15. Children’s Benadryl Allergy Drug Facts Label. 16. Children’s Allegra Oral Suspension Drug Facts Label. 17. Children’s Claritin Chewable Drug Facts Label. 18. Children’s Nasacort Drug Facts Label. 19. Children’s Zyrtec Drug Facts Label. 20. Derendorf, H. and Meltzer, E. O. Molecular and Clinical Pharmacology of Intranasal Corticosteroids: Clinical and Therapeutic Implications. Allergy: European Journal of Allergy and Clinical Immunology. 63(10): 1292-1300, 2008. 21. Gelfand, E. W. Inflammatory Mediators in Allergic Rhinitis. Journal of Allergy and Clinical Immunology. 114(5 SUPPL.): S135-S138, 2004. 22. White, M. V. and Kaliner, M. A. Mediators of Allergic Rhinitis. Journal of Allergy and Clinical Immunology. 90(4 II): 699-704, 1992. 23. Bachert, C. and Geveart, P. Effect of Intranasal Corticosteroids on Release of Cytokines and Inflammatory Mediators. Allergy: European Journal of Allergy and Clinical Immunology, Supplement. 54(57): 116-123, 1999. 24. Van As, A., Bronsky, E., Grossman, J., Meltzer, E. et al. Dose Tolerance Study of Fluticasone Propionate Aqueous Nasal Spray in Patients With Seasonal Allergic Rhinitis. Annals of Allergy. 67(2 I): 156-162, 1991. 25. Meltzer, E. O., Orgel, H. A., Bronsky, E. A., Furukawa, C. T. et al. A Dose-Ranging Study of Fluticasone Propionate Aqueous Nasal Spray for Seasonal Allergic Rhinitis Assessed by Symptoms, Rhinomanometry, and Nasal Cytology. Journal of Allergy and Clinical Immunology. 86(2): 221-230, 1990. 26. Greiner, A. N. and Meltzer, E. O. Overview of the Treatment of Allergic Rhinitis and Nonallergic Rhinopathy. Proceedings of the American Thoracic Society. 8(1): 121-131, 2011. 27. Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J. et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 Update (in Collaboration With the World Health Organization, GA2LEN and AllerGen). Allergy: European Journal of Allergy and Clinical Immunology. 63(SUPPL. 86): 8-160, 2008. 28. Daley-Yates, P. T., Kunka, R. L., Yin, Y., Andrews, S. M. et al. Bioavailability of Fluticasone Propionate and Mometasone Furoate Aqueous Nasal Sprays. European Journal of Clinical Pharmacology. 60(4): 265-268, 2004. 29. Daley-Yates, P. T. and Baker, R. C. Systemic Bioavailability of Fluticasone Propionate Administered As Nasal Drops and Aqueous Nasal Spray Formulations. British Journal of Clinical Pharmacology. 51(1): 103-105, 2001.